Stock Taper
SBFMW
SUNSHINE BIOPHARMA, INC.
NASDAQ
$0.03
▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$155.18 K
52w High$0.24
52w Low$0.03
Dividend Yield
Frequency
P/E
Volume0
Shares Out.5.01M

COMPANY

LEADERSHIP

Steve N. Slilaty
CHIEF EXECUTIVE
Steve N. Slilaty

COMPENSATION 2026

Salary$411,587
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$1,211,587

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 15, 2022
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
50

UPCOMING EARNINGS

DateNov 10, 2026
DayTuesday
Rev. Est.$9.60M
NOV
10
TUE

PRICE

$0.03 ▲ UP 0.00% (+$0.00)
$0.03$0.03$0.03$0.039:33 AM9:38 AM9:43 AM9:48 AM9:53 AM9:58 AM10:03 AM0.03

About Sunshine Biopharma, Inc.

https://www.sunshinebiopharma.com ↗

Sunshine Biopharma, Inc. develops anticancer drugs like Adva-27a and anti-coronavirus treatments, alongside nutritional supplements, focusing on innovative therapies for various cancers and resistant diseases.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT SUNSHINE BIOPHARMA, INC. IS KNOWN FOR

Domperidone
Domperidone

A generic prescription drug launched in Canada to treat nausea and vomiting. Its recent regulatory approval and market introduction represent a significant commercial milestone for the company's revenue-generating generic pharmaceuticals division.

INSTITUTIONAL OWNERSHIP

SHARES OWNED
0.78%
HOLDERS
4
TOP 4 OF 4 · RANKED BY POSITION SIZE
Ubs Group AG
23.9K sh · $1.79K
Empery Asset Management, LP
15.0K sh · $7K
Clear Street LLC
94 sh · $27
Concourse Financial Group Securities, Inc.
0 sh · $0

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book5
Overall Score2

INSIDER TRADES

DIRECTOR
NATAN DAVID
Purchase · 58.3K shares
2026-08-07
DIRECTOR
NATAN DAVID
Purchase · 100.0K shares
2026-04-14

SECTORS PEERS

PEERPRICE
NRSN$0.47COMPARE
BFRI$1.27COMPARE
LFWD$7.68COMPARE
PHIO$1.04COMPARE
INAB$0.98COMPARE
APVO$4.18COMPARE
RNAZ$3.96COMPARE
SBFM$1.13COMPARE